BIOVERSYS
Bioversys AG is a privately held Swiss biopharmaceutical company located in Basel that focuses on research and development of new drugs and compounds, which switch-off drug resistance within bacterial pathogens and restore the efficacy of approved antibiotics. Spun out of the ETH-Zurich in 2008, we have profound technological expertise that is based on solid IP.
BIOVERSYS
Industry:
Biotechnology Pharmaceutical
Founded:
2008-01-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.bioversys.com
Total Employee:
1+
Status:
Active
Contact:
+41 78 670 40 85
Total Funding:
90.76 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Adrenomed
Adrenomed is a privately-financed, clinical-stage biopharmaceutical company.
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Cyclerion Therapeutics
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company.
Frontier Biotechnologies
Frontier Biotechnologies is a commercial-stage bio-pharmaceutical company.
IntraBio
IntraBio is a biopharmaceutical company.
Jenrin Discovery
Jenrin Discovery is a biopharmaceutical Company.
Molecular Partners
Molecular Partners is a clinical-stage biopharmaceutical company.
NPK Biotest
NPK Biotest is a privately held pharmaceutical company.
Nymox Pharmaceutical
Nymox Pharmaceutical is a biopharmaceutical company.
Obexia
Obexia is a privately held biopharmaceuticals start-up company based in Basel.
Ocugen
Ocugen is a clinical stage biopharmaceutical company.
Current Advisors List
Board_member
Current Employees Featured
Sergio Lociuro CSO @ BioVersys
CSO
Marc Gitzinger CEO & Co-Founder @ BioVersys
CEO & Co-Founder
2010-12-01
Founder
Investors List
CARB-X
CARB-X investment in Grant - BioVersys
European Investment Bank
European Investment Bank investment in Debt Financing - BioVersys
Business Angels Switzerland (BAS)
Business Angels Switzerland (BAS) investment in Series B - BioVersys
CARB-X
CARB-X investment in Grant - BioVersys
Business Angels Switzerland (BAS)
Business Angels Switzerland (BAS) investment in Series A - BioVersys
GoBeyond
GoBeyond investment in Seed Round - BioVersys
BioValley Business Angels Club (BioBAC)
BioValley Business Angels Club (BioBAC) investment in Seed Round - BioVersys
EVA Basel
EVA Basel investment in Seed Round - BioVersys
Venture Kick
Venture Kick investment in Pre Seed Round - BioVersys
Venture Kick
Venture Kick investment in Grant - BioVersys
Newest Events participated
Official Site Inspections
http://www.bioversys.com Semrush global rank: 8.53 M Semrush visits lastest month: 300
- Host name: chaplin.sui-inter.net
- IP address: 94.126.16.60
- Location: Switzerland
- Latitude: 47.1449
- Longitude: 8.1551
- Timezone: Europe/Zurich
More informations about "BioVersys"
Team | Meet the Resistance Fighters - www.bioversys.com
Jonathan joined BioVersys in May 2018 and leads the business development activities with passion and dedication. Within a short time, Jonathan impacted the business of BioVersys …See details»
BioVersys - Crunchbase Company Profile & Funding
BioVersys is developing a range of new mode of action compounds targeting Gram-negative, Gram-positive, and Tuberculosis bacteria to address unmet …See details»
Executive Committee | BioVersys
BIOVERSYS AG - Our Investor Relations section provides key insights into our financial performance, corporate strategy, and latest developments. You will find essential information …See details»
Investors | BioVersys
Feb 4, 2025 BIOVERSYS AG. Investors Hernan Levett CFO hernan.levett@bioversys.com +41 61 551 51 42. Media Thomas Schneckenburger media@bioversys.com +41 79 4079952. …See details»
BIOVERSYS AG - Investor Relations
BIOVERSYS AG - Our Investor Relations section provides key insights into our financial performance, corporate strategy, and latest developments. You will find essential information …See details»
BioVersys AG Company Profile | Basel, BASEL-STADT, Switzerland ...
Find company research, competitor information, contact details & financial data for BioVersys AG of Basel, BASEL-STADT. Get the latest business insights from Dun & Bradstreet.See details»
BioVersys AG – Swiss Biotech
BioVersys AG is a privately held Swiss pharmaceutical company focusing on R&D of small molecules acting on novel bacterial targets with applications in Anti-Microbial Resistance (AMR) and targeted microbiome modulation. ... Type of …See details»
BioVersys - Funding, Financials, Valuation & Investors - Crunchbase
BioVersys is registered under the ticker SIX:BIOV . Their stock opened with CHF36.00 in its Feb 7, 2025 IPO. Stock Symbol SIX:BIOV ; Valuation at IPO CHF213M; Money Raised at IPO …See details»
BioVersys GmbH - VentureRadar
" BioVersys AG is a privately-owned clinical stage Swiss pharmaceutical company focusing on research and development of small molecules acting on novel bacterial targets with …See details»
BioVersys: saving lives in resistant times - media.nature.com
The Swiss pharmaceutical company BioVersys is developing next-generation antimicrobial drugs with unique modes of action targeting a range of multidrug-resistant bacteria. ... recognized as …See details»
BioVersys: saving lives in resistant times - Nature
Antimicrobial resistance (AMR) is predicted to cause 10 million deaths by 2050 and is widely recognized as the biggest threat to human health by the World Health Organization (WHO) …See details»
BioVersys. Information about the issuer. . News and credit ratings ...
BioVersys AG operates as a biopharmaceutical company. The Company focuses on developing small molecules for multidrug-resistant bacterial infections with applications in anti-microbial …See details»
BioVersys Announces Expansion of Strategic Collaboration with …
May 7, 2024 BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections …See details»
Financials | BioVersys
Mar 26, 2025 BIOVERSYS AG - Our Investor Relations section provides key insights into our financial performance, corporate strategy, and latest developments. You will find essential …See details»
AMR biotech BioVersys plans to float on Swiss stock exchange
Feb 26, 2025 BV100 is a new formulation of rifabutin suitable for intravenous administration, which BioVersys claims offers a new mechanism of action that circumvents carbapenem …See details»
BioVersys Announces Important BV100 Patent Granted by
6 days ago BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life …See details»
Patients - BioVersys
Recognized by esteemed global organizations like the World Health Organization (WHO), the G7, and the G20, AMR poses an imminent and present danger to our current way of life that could …See details»
BIOVERSYS REPORTS CORPORATE HIGHLIGHS AND KEY
Mar 26, 2025 BioVersys will host a conference call and webcast at 2.00 pm CET (8.00 am EST) t o discuss the financial results, provide an update on the company’s performance, outline its …See details»
BIOVERSYS AG - Our Investor Relations section provides key …
Mar 19, 2025 Under the BioVersys and GSK collaboration agreement, GSK is evaluating the early bactericidal activity (EBA) of alpibectir-ethionamide (AlpE) in a pulmonary tuberculosis …See details»
BioVersys Reports Corporate Highlights and Key Financials for the …
Mar 26, 2025 Initial Public Offering in Q1 2025 On the back of the promising advancement of the company’s pipeline and the related positive clinical data generated, BioVersys successfully …See details»